The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma

Respiratory Research

Volumn 5, Issue , 2004, Pages

  Clayton, Robert A ^a   Dick, Colin A J ^a   Mackenzie, Alison ^a   Nagasawa, Michiaki ^b   Galbraith, Deirdre ^c   Hastings, Stuart F ^a   MacKenzie, Simon J ^a  

^a Scottish Biomedical   (United Kingdom)

^b KYORIN PHARMACEUTICAL CO LTD   (Japan)

^c UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; CILOSTAZOL; DEXAMETHASONE; IMMUNOGLOBULIN E; INTERLEUKIN 4; INTERLEUKIN 5; OVALBUMIN; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; CYTOKINE;

ALLERGIC ASTHMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; EOSINOPHIL; IMMUNOGLOBULIN BLOOD LEVEL; LEUKOCYTE DIFFERENTIAL COUNT; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; SENSITIZATION; ANIMAL; ASTHMA; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CYTOLOGY; DISEASE MODEL; DRUG COMBINATION; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; MALE; MICE; MICE, INBRED BALB C; OVALBUMIN; PHOSPHODIESTERASE INHIBITORS; TREATMENT OUTCOME;

EID: 23844530650     PISSN: 1465993X     EISSN: None     Source Type: Journal    
DOI: 10.1186/1465-9921-5-4     Document Type: Article

References (46)

1. Houslay MD, Milligan G: Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem Sci 1997, 22:217-224.
2. Houslay MD: Adaption in cAMP signalling processes: a central role in cyclic AMP phosphodiesterases. Sem Cell Dev Biol 1998, 9:161-167.
3. Beavo JA: Cyclic nucleotide phosphodiesterase: functional implications of multiple isoforms. Physiol Rev 1995, 75:725-748.
4. Bolger GB: Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell Signal 1994, 6:851-859.
5. Loughney K, Ferguson K: Identification and quantification of PDE isoenzymes and subtypes by molecular biological methods. In Phosphodiesterase inhibitors Edited by: Schudt C, Dent G, Rabe KF. London: Academic Press; 1996:1-19.
6. Soderling SH, Bayuga SJ, Beavo JA: Identification and characterisation of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 1998, 273:15553-15558.
7. Schror K: The pharmacology of Cilostazol. Diabetes Obes Metab 2002, 4:S14-19.
8. Corbin JD, Francis SH, Webb DJ: Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology 2002, 60:4-11.
9. Barnette MS: Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). Prog Drug Res 1999, 53:193-229.
10. Souness JE, Aldous D, Sargent C: Immunosuppressive and antiinflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacol 2000, 47:127-162.
11. Giembycz MA: Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch Chest Dis 2002, 57:48-64.
12. Houslay MD: PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol 2001, 69:249-315.
13. Schudt C, Tenor H, Hatzelmann A: PDE isoenzymes as targets for anti-asthma drugs. Eur Respir J 1995, 8:1179-1183.
14. m cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig. J Pharmacol Exp Ther 1989, 251:199-206.
15. Heaslip RJ, Buckley SK, Sickels BD, Grimes D: Bronchial vs cardiovascular activities of selective phosphodiesterase inhibitors in the anaesthetized beta-blocked dog. J Pharmacol Exp Ther 1991, 257:741-7.
16. Miyamoto K, Kurita M, Sakai R, Sanae F, Wakusawa S, Takagi K: Cyclic nucleotide phosphodiesterase isoenzymes in guinea pig tracheal muscle and bronchorelaxation by alkylxanthines. Biochem Pharmacol 1994, 48:1219-1223.
17. Banner KH, Page CP: Immunomodulatory actions of xanthines and isoenzyme selective phosphodiesterase inhibitors. Monaldi Arch Chest Dis 1995, 50:286-292.
18. Giembycz MA, Dent G: Prospects for selective nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma. Clin Exp Allergy 1992, 22:337-344.
19. Giembycz MA, Dent G, Souness JE: Theophyline and isoenzyme selective phosphodiesterase inhibitors. In: Allergy & Allergic diseases Edited by: Kay AB. London: Blackwell Scientific; 1997:531-567.
20. Torphy TJ: Molecular targets for the novel anti-asthma agents. Am J Respir Crit Care Med 1998, 157:351-370.
21. Torphy TJ, Undem BJ: Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 1991, 46:512-523.
22. Howell RE, Jenkins LP, Fielding LE, Grimes D: Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats. Pulm Pharmacol 1995, 8:83-89.
23. Underwood DC, Kotzer CJ, Bochniwicz S, Osborn RR, Luttmann MA, Hay DWP, Torphy TJ: Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pig. J Pharmacol Exp Ther 1994, 270:250-259.
24. Schleimer RP: Effects of glucocorticoids on inflammatory cells relevant to their therapeutic applications in asthma. Am Rev Respir Dis 1990, 141:S59-S69.
25. Schmidt DT, Watson N, Dent G, Ruhlmann E, Branscheid D, Magnussen H, Rabe KF: The effect of selective and non selective phosphodiesterase inhibitors on allergen- and leukotriene C4-induced contractions in passively sensitised human airways. Br J Pharmacol 2000, 131:1607-1618.
26. Santing RE, de Boer J, Rohof A, van der Zee NM, Zaagsma J: Bronchodilatory and anti-inflammatory properties of inhaled selective phosphodiesterase inhibitors in a guinea pig model of allergic asthma. Eur J Pharmacol 2001, 429:335-44.
27. Teixeira MM, Rossi AG, Williams TJ, Hellewell PG: Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea pig. Br J Pharmacol 1994, 112:332-340.
28. Kung TT, Jones H, Adams GK, Umland SP, Kreutner W, Egan Chapman RW, Watnick AS: Characterisation of a murine model of allergic pulmonary inflammation. Int Arch Allergy Immunol 1994, 105:83-90.
29. Thompson WJ, Appleman MM: Multiple cyclic nucleotide Phosphodiesterase activities from rat brain. Biochem 1971, 10:311-316.
30. Corbin JD, Francis SH: Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002, 56:453-459.
31. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R: In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001, 297:280-290.
32. Toward TJ, Smith N, Broadley KJ: Effect of Phosphodiesterase-5 Inhibitor, Sildenafil (Viagra), in Animal Models of Airways Disease. Am J Resp Crit Care Med 2004, 169:227-234.
33. Barnett MS, Manning CD, Cieslinski LB, Burman M, Christensen SB, Torphy TJ: The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity. J Pharmacol Exp Ther 1995, 273:674-679.
34. Santamaria LF, Palacios JM, Beleta J: Inhibition of eotaxin-mediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram. Br J Pharmacol 1997, 121:1150-1154.
35. Barnette MS, Bartus JO, Burman M, Christensen SB, Cieslinski LB, Esser KM, Prabhakar US, Rush JA, Torphy TJ: Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H] rolipram binding. Biochem Pharmacol 1996, 51:949-56.
36. Das AM, Flower RJ, Hellewell PG, Teixeira MM, Perretti M: A novel murine model of allergic inflammation to study the effect of dexamethasone on eosinophil recruitment. Br J Pharmacol 1997, 121:97-104.
37. Torphy TJ, Barnette MS, Hay DW, Underwood DC: Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma. Environ Health Perspect 1994, 102(suppl 10):79-84.
38. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, Heusser CH, Howarth PH, Holgate ST: Interleukin-4, -5, and -6 and tumour necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994, 10:471-480.
39. Cieslewicz G, Tomkinson A, Adler A, Duez C, Schwarze J, Takeda K, Larson KA, Lee JJ, Irvin C, Gelfand EW: The late, but not early, asthmatic response is dependent on IL-5 and correlates with eosinophil infiltration. J Clin Invest 1999, 104:301-308.
40. Broide DH, Lotz M, Cuomo AJ, Coburn DA, Federman EC, Wasserman SI: Cytokines in symptomatic asthma airways. J Allergy Clin Immunol 1992, 89:958-967.
41. Prabhakar U, Lipshutz D, Bartus JO, Slivjak MJ, Smith EF, Lee JC, Esser KM: Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int J Immunopharmacol 1994, 16:805-816.
42. Semmler J, Wachtel H, Endres S: The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells. Int J Immunopharmacol 1993, 15:409-413.
43. Badger AM, Olivera DL, Esser KM: Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock. Circ Shock 1994, 44:188-195.
44. Hatzelmann A, Schudt C: Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001, 297:267-279.
45. Takei K, Tokuyama K, Kato M, Morikawa A: Role of cyclic adenosine monophosphate in reducing superoxide anion generation in guinea pig alveolar macrophages. Pharmacol 1998, 57:1-7.
46. Silva PMR, Alves AC, Serra MF, Lucia A, Pires A, Silva JP, Barreto EO, Corderio RSB, Jose PJ, Teixeria MM, Lagnette V, Martins MA: Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme. Br J Pharmacol 2001, 134:283-294.